Allogene Therapeutics’ Promising Clinical Trial Advances and Strategic Positioning: A Buy Recommendation by Tyler Van Buren
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ALLO stock, giving a Buy rating on October 30. Tyler Van Buren’s ...
Gilead Sciences: Strong Financial Performance and Promising Outlook Underpin Buy Rating
In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a ...